Reuters Health adds new executive editor

Share this article:
Reuters Health adds new executive editor
Reuters Health adds new executive editor
Reuters Health hired Ivan Oransky as executive editor, heading editorial operations for the company's global medical and healthcare news services. The appointment is effective June 15.

“Joining Reuters Health is a great opportunity to lead a talented team that has built a highly authoritative, comprehensive and successful news service over the years,” Oransky told the Association of Health Care Journalists (AHCJ). Oransky was elected to the AHCJ's board in 2002.

Vincent Baby, VP of news services for Reuters News Agency, said in a statement that Oransky's academic and professional track record “make him the ideal person to develop Reuters Health and further leverage the unique assets of Thomson Reuters in the scientific and healthcare arena for the benefit of our professional and media customers.”

Oransky was previously an online managing editor at Scientific American, where he oversaw “significant content expansion and high traffic growth,” according to a statement. In addition to AHCJ, Oransky is also a member of the National Association of Science Writers.

The move follows the planned retirement of Robert Saunders, who has been at the editorial helm of Reuters Health for over a decade.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.